Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tendocolinn is a dietary supplement developed by INNventa Pharm, specifically formulated to support the health and structural integrity of tendons and ligaments. The product contains TENDOFORTE®, a proprietary composition of bioactive collagen peptides that are optimized to stimulate the metabolic activity of tenocytes. By activating these cells, Tendocolinn promotes the biosynthesis of type I collagen and other extracellular matrix components essential for connective tissue repair and stability. The formulation is further enhanced with Vitamin C and Manganese, which serve as critical cofactors for the enzymatic processes involved in collagen maturation and the maintenance of normal connective tissue. It is primarily indicated for individuals recovering from tendinopathies, ligamentous injuries, and for athletes seeking to reduce the risk of sports-related soft tissue injuries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tendocolinn.